Valneva SE Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the month of March 2026 for Valneva SE, a foreign private issuer. The filing reports on the topline results of the Phase 3 VALOR clinical trial for the investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V), developed in collaboration with Pfizer Inc.
Key Financial Metrics
The filing text does not provide specific financial data regarding revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial outcomes and regulatory strategy.
Material Changes and Clinical Results
On March 23, 2026, Valneva and Pfizer announced the following results for LB6V in individuals aged five years and above:
- Efficacy: The vaccine demonstrated more than 70% efficacy in preventing Lyme disease with no identified safety concerns.
- Primary Endpoint Analysis: Efficacy of 73.2% from 28 days post-dose 4 (season 2) compared to placebo (95% CI 15.8, 93.5).
- Secondary Analysis: Efficacy of 74.8% from 1-day post-dose 4 (season 2) compared to placebo (95% CI 21.7, 93.9).
- Statistical Outcome: Fewer Lyme disease cases were accrued than anticipated. Consequently, the pre-determined statistical criterion (95% confidence interval lower bound >20) was not met in the first pre-specified analysis (primary endpoint). However, the criterion was met in the second pre-specified analysis.
Guidance, Outlook, and Risks
Despite the primary endpoint not meeting the strict statistical threshold due to lower-than-expected case accrual, Pfizer expressed confidence in the vaccine's potential given the clinically meaningful efficacy and the success of the second analysis. The company is planning submissions to regulatory authorities. The filing includes standard forward-looking statement disclaimers regarding uncertainties in development, manufacturing, regulatory actions, and competition.
Investor Verification Checklist
- Verify the specific regulatory submission timeline and target agencies (e.g., FDA, EMA) for LB6V.
- Confirm the financial impact of the collaboration agreement with Pfizer, including potential milestone payments triggered by these results.
- Review the detailed statistical analysis plan to understand the implications of the lower-than-expected case accrual on future regulatory approval.
- Monitor for any updates on the safety profile as the study data matures beyond the topline analysis.